e-ISSN (online): 2745-9497

Journal of Anesthesiology and Clinical Research (JACR)

Journal website: https://hmpublisher.com/index.php/jacr

Acute Motor Axonal Neuropathy with Respiratory Failure: A Case Report on the Clinical Course Following a Single Session of Therapeutic Plasma Exchange

Wirjapratama Putra[1*], Septian Adi Permana[1], Ellen Josephine Handoko[2]

[1]Department of Anesthesiology and Intensive Therapy, Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

[2]Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia

ARTICLE INFO

Keywords:
Acute motor axonal neuropathy
Critical care
Guillain-Barré syndrome
Single session
Therapeutic plasma exchange

***Corresponding author:**
Wirjapratama Putra

E-mail address:
wirjapratamapp@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/jacr.v6i2.775

A B S T R A C T

Introduction: Guillain-Barré syndrome (GBS) is a severe, immune-mediated peripheral neuropathy. The acute motor axonal neuropathy (AMAN) variant, characterized by a direct antibody attack on motor axons, often leads to rapid, severe paralysis. Standard immunotherapy for severe GBS involves a multi-session course of therapeutic plasma exchange (TPE) or Intravenous Immunoglobulin (IVIg). **Case presentation:** We present the case of a 68-year-old male with rapidly progressive GBS, confirmed as the AMAN subtype through clinical, cerebrospinal, and electrophysiological findings. The patient developed flaccid quadriparesis and acute respiratory failure, necessitating emergent intubation and mechanical ventilation in the intensive care unit (ICU). Following a single, large-volume session of TPE, a marked and rapid clinical improvement was observed. The patient was successfully weaned from mechanical ventilation and transferred from the ICU within three days of the intervention. **Conclusion:** This case documents a noteworthy temporal association between a single TPE session and rapid clinical recovery in a patient with ventilator-dependent AMAN-GBS. While a causal relationship cannot be definitively established due to the disease's natural history, the observation prompts a deep exploration of the underlying pathophysiology. The discussion theorizes how a single, well-timed intervention might profoundly disrupt the autoimmune cascade by affecting peak antibody titers, complement activation, and cytokine kinetics.

1. Introduction

Guillain-Barré syndrome (GBS) represents a constellation of acute, immune-mediated polyradiculoneuropathies, constituting the most common cause of acute flaccid paralysis worldwide. With a global prevalence estimated at 0.4 to 4 cases per 100,000 population annually, GBS poses a significant diagnostic and therapeutic challenge to clinicians across various specialties, including neurology, emergency medicine, and critical care.[1] The incidence demonstrates a bimodal distribution, with peaks in young adulthood and in the elderly, with a slight male preponderance. While many patients recover, GBS carries a substantial burden of morbidity and mortality; up to 30% of patients develop respiratory failure requiring mechanical ventilation, and mortality rates can approach 5-10% even with modern intensive care.[2]

The pathogenesis of GBS is rooted in an aberrant autoimmune response directed against components of the peripheral nervous system.[3] This autoimmune cascade is often triggered by an antecedent event, most commonly an infection. Approximately 75% of patients report an upper respiratory or gastrointestinal illness in the one to four weeks preceding the onset of

neurological symptoms. The most frequently identified infectious trigger is *Campylobacter jejuni*, particularly in axonal forms of the disease. Other associated pathogens include Cytomegalovirus (CMV), Epstein-Barr virus, and Zika virus. Less commonly, GBS has been linked to vaccinations or surgery.[3] The prevailing hypothesis is that of "molecular mimicry," where surface molecules on the infectious agent, such as the lipo-oligosaccharides of *C. jejuni*, resemble gangliosides on the surface of peripheral nerves. This molecular similarity leads to the production of cross-reactive antibodies that, after clearing the infection, erroneously target and damage the host's nerve tissues.

GBS is not a single entity but a heterogeneous syndrome with several subtypes distinguished by their electrophysiological and pathological features.[4] The most common form in North America and Europe is Acute Inflammatory Demyelinating Polyneuropathy (AIDP), characterized by a T-cell-mediated inflammatory response and macrophage-induced stripping of myelin from the nerve sheath.[5] In contrast, the axonal subtypes, Acute Motor Axonal Neuropathy (AMAN) and Acute Motor-Sensory Axonal Neuropathy (AMSAN), are more prevalent in Asia and Latin America. The AMAN variant, central to the case presented herein, is primarily a humorally-mediated disease. It involves the production of IgG antibodies against specific gangliosides (such as GM1, GD1a, and GalNAc-GD1a) concentrated at the nodes of Ranvier in motor axons. The binding of these autoantibodies activates the complement cascade, leading to the formation of the membrane attack complex, disruption of the axolemma, and subsequent axonal degeneration, all without significant primary inflammation or demyelination.[5] This distinct pathophysiology of a direct axonal attack often correlates with a more rapid onset of weakness and, in some cases, a more prolonged or incomplete recovery compared to AIDP.

The clinical hallmark of GBS is a rapidly progressive, relatively symmetrical weakness, often beginning in the lower extremities and ascending over hours to days. Areflexia or hyporeflexia is a cardinal sign.[6] While AIDP often involves significant sensory symptoms, AMAN is typically a purely motor syndrome. Autonomic dysfunction is common and can be life-threatening, manifesting as tachyarrhythmias, bradycardia, labile hypertension, or profound hypotension.[6] A critical complication is respiratory failure, resulting from weakness of the diaphragm and intercostal muscles, which necessitates vigilant monitoring and, frequently, intensive care unit (ICU) admission for mechanical ventilation.

The diagnosis of GBS is primarily clinical, supported by ancillary investigations. Cerebrospinal fluid (CSF) analysis classically reveals albuminocytologic dissociation—an elevated protein level with a normal white blood cell count—typically appearing after the first week of symptoms. Electrophysiological studies are crucial for confirming the diagnosis and, importantly, for distinguishing between demyelinating and axonal subtypes, which have prognostic implications.[7]

Management of GBS is twofold: intensive supportive care and specific immunotherapy. Supportive care, often orchestrated by anesthesiologists and intensivists, is the cornerstone of treatment for severe cases.[8] This includes airway management, mechanical ventilation, cardiovascular monitoring and support, pain control, deep vein thrombosis prophylaxis, and nutritional support. Two immunomodulatory treatments have been proven effective in hastening recovery in patients with GBS who are unable to walk unaided: Intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (TPE). Both treatments are of equal efficacy in improving disability outcomes. Corticosteroids, despite their use in other autoimmune conditions, have been shown to be ineffective and are not recommended. The standard regimen for IVIg is a total dose of 2 g/kg administered over five days. The standard protocol for TPE consists of a series of five to six exchanges performed over 10 to 14 days.[9]

The established TPE protocol for GBS is based on evidence accumulated over decades, with a consensus that multiple sessions are required to effectively deplete the total body burden of pathogenic autoantibodies.[10] Reports on the efficacy of abbreviated or single-session TPE protocols, especially in severe, ventilator-dependent GBS, are virtually non-existent in the medical literature. The novelty of this case report lies in its detailed documentation of an exceptionally rapid clinical recovery in a patient with the severe AMAN

variant of GBS following a stark deviation from this standard of care—a single TPE session. This presents a unique clinical observation that challenges conventional pharmacokinetic assumptions and provides a rare opportunity to explore the theoretical underpinnings of the therapeutic mechanisms of TPE in acute humoral autoimmunity.[10] The primary aim of this case report is to meticulously document the clinical course, diagnostic findings, and therapeutic management of a critically ill patient with the AMAN variant of GBS who demonstrated an unexpected trajectory of recovery after a single session of TPE. A secondary aim is to delve deeply into the potential pathophysiological mechanisms that could theoretically explain this observation, fostering a scientific discussion on the interplay between the timing of intervention and the dynamic kinetics of the autoimmune process in GBS. This report seeks to generate hypotheses for future research rather than to advocate for a change in current clinical practice.

2. Case Presentation

A 68-year-old male presented with a clinical profile that strongly suggested a rapidly evolving, severe neurological disorder. The patient, who had been fully independent and active prior to this illness, offered a baseline of good health, making the subsequent events particularly stark. His past medical history was unremarkable, with no known chronic illnesses such as diabetes or autoimmune conditions that might otherwise predispose him to neuropathy. This lack of comorbidities focused the diagnostic lens squarely on an acute, de novo process. Furthermore, his social history as a non-smoker and non-drinker effectively ruled out common toxic etiologies for peripheral nerve damage. The clinical narrative began three weeks prior to his initial assessment, with the insidious onset of progressive weakness affecting all four limbs. This subacute timeframe is characteristic of Guillain-Barré syndrome (GBS) and its variants, distinguishing it from hyperacute events like stroke. The primary complaint was accompanied by a constellation of associated symptoms highly indicative of polyradiculoneuropathy. He reported paresthesias in his hands and feet, consistent with the classic "glove and stocking" sensory disturbance seen in peripheral nerve disorders. The presence of lower back pain suggested an inflammatory process involving the nerve roots (radiculitis), a common and often distressing early feature of GBS. In the search for a potential trigger, a crucial aspect of the GBS diagnostic pathway, the history was notable for what it lacked. There were no reported antecedent events, specifically no recent history of diarrheal illness, which is a classic trigger for the AMAN variant of GBS, often linked to *Campylobacter jejuni*. The patient did report a cough, which, while non-specific, could hint at a preceding upper respiratory tract infection, another well-documented catalyst for the autoimmune response in GBS. Figure 1 holistically portrays the initial presentation of a previously healthy older adult suddenly afflicted by a symmetrical, ascending weakness accompanied by sensory and radicular symptoms. The profile is scientifically informative, highlighting both the positive findings that point towards GBS and the pertinent negatives that exclude common differential diagnoses, thereby setting a clear trajectory for the subsequent diagnostic workup.

Figure 2 showed a detailed and dramatic timeline of the patient's clinical journey, illustrating a rapid progression to life-threatening illness followed by an equally swift recovery. The narrative began in the pre-admission phase, spanning approximately three weeks, during which the patient experienced the classic subacute onset of Guillain-Barré syndrome. This period was characterized by progressive, ascending weakness and sensory symptoms that methodically eroded his functional capacity, taking him from a state of full independence to being unable to walk. This initial phase culminated on Day 1 with his admission to the neurology ward, signifying the point at which the severity of his quadriparesis necessitated formal diagnostic investigation and hospital-level care. For three days, the patient's condition was managed on the ward, but on Day 4, the illness reached its clinical nadir. This critical turning point was marked by a fulminant deterioration, as the patient's worsening weakness precipitated acute respiratory failure. This life-threatening event required emergent intervention, including endotracheal intubation and transfer to the intensive care unit (ICU) for mechanical ventilation. The

day following this crisis, on Day 5, the primary therapeutic intervention was administered. A single, large-volume session of therapeutic plasma exchange (TPE) was performed as the sole immunomodulatory therapy. What followed was a remarkable and rapid reversal of the patient's critical state. By Days 6 and 7, a marked clinical improvement was noted, allowing for the initiation of weaning from mechanical ventilation. The recovery was so prompt that successful extubation was achieved on Day 7. This rapid stabilization culminated on Day 8 with the patient's discharge from the ICU back to the neurology ward for continued rehabilitation. The entire ICU course, from respiratory collapse to stabilization and discharge, spanned only four days, with the therapeutic intervention positioned precisely at the pivot point between deterioration and recovery.

Figure 3 showed a dramatic clinical tableau, presenting a side-by-side comparative analysis of the patient's neurological status at two pivotal moments: his initial admission to the neurology ward and his subsequent transfer to the intensive care unit. This visual juxtaposition provides a powerful, quantitative narrative of the patient's rapid and catastrophic clinical deterioration over a mere three-day period, encapsulating the fulminant nature of severe Guillain-Barré Syndrome. On Day 1, the left panel depicts a patient who, while significantly impaired, was neurologically stable. His consciousness was unimpaired, with a glasgow coma scale (GCS) score of 15/15, and his cranial nerve functions were entirely intact. This preservation of higher cortical and brainstem function is a key diagnostic clue, pointing away from central nervous system pathologies and towards a primary peripheral process. The core of the pathology was clearly in the motor system. He presented with severe quadriparesis, with motor strength graded on the Medical Research Council (MRC) scale as 3/5 in the upper extremities (indicating movement against gravity but not resistance) and a more profound 2/5 in the lower extremities (indicating movement only with gravity eliminated). This ascending pattern of weakness is classic for GBS. The hallmark sign of areflexia was already evident in the lower limbs, with diminished reflexes in the upper limbs, confirming the diagnosis of a polyradiculoneuropathy. Functionally, these deficits culminated in a GBS Disability Score of 4, defining him as bed- or chair-bound—a state of severe disability. In stark contrast, the right panel for Day 4 illustrates a patient in clinical freefall, having reached the nadir of his illness. While his cranial nerves remained remarkably spared, every other neurological parameter had worsened significantly. His consciousness had subtly declined to a GCS of 14/15, not from a primary neurological insult, but from the restlessness and anxiety characteristic of air hunger and impending respiratory collapse. The motor examination revealed a devastating progression to near-total paralysis. Strength in the upper extremities had fallen to 2/5, and the lower extremities were reduced to a flicker of movement, graded at 1/5. Correspondingly, the initial pattern of diminished and absent reflexes had evolved into a state of complete, global areflexia in all limbs. This precipitous decline in motor function is directly reflected in the GBS Disability Score, which escalated from 4 to 5—the scale's most severe level, defined by the requirement for mechanical ventilation to sustain life. Figure 3 scientifically documents the patient's transition from severe disability to critical, life-threatening illness. It visually confirms the key features of GBS—the sparing of consciousness and cranial nerves in the face of catastrophic peripheral motor failure—and quantifies the severity that mandated emergent ICU admission and aggressive immunomodulatory therapy.

Figure 4 showed the results of the comprehensive diagnostic workup, presenting a clear and methodical narrative of how the patient's diagnosis was confirmed while excluding other critical pathologies. The investigations collectively built an unassailable case for the specific and severe variant of Guillain-Barré syndrome. The process began with the cerebrospinal fluid (CSF) Analysis, which provided the first piece of pivotal objective evidence. The finding of an elevated protein level in the absence of an elevated cell count represents the classic "albuminocytologic dissociation." Scientifically, this indicates a breakdown of the blood-nerve barrier at the level of the nerve roots, allowing protein to leak into the CSF, without the signs of a central nervous system infection like meningitis. This

finding is a strong hallmark of GBS and steered the diagnostic process firmly in the direction of an autoimmune polyradiculoneuropathy. Next, Electrophysiology provided the definitive and most detailed part of the diagnosis with forensic precision. The nerve conduction studies were pathognomonic. The complete absence of motor responses (Compound Muscle Action Potentials and F-waves) in all tested nerves confirmed a severe, widespread disruption of motor axon function. Critically, the sensory nerve responses were normal. This dissociation between motor and sensory findings is the defining feature that differentiates the acute motor axonal neuropathy (AMAN) variant from other forms of GBS. These results did more than just support the diagnosis; they pinpointed the exact subtype of the disease, which has significant prognostic and pathophysiological implications. With the primary diagnosis confirmed, the remaining investigations served to rule out critical confounders that could mimic or complicate the clinical picture. The Microbiology results from blood cultures, showing growth of *Micrococcus luteus*, were correctly interpreted as a common skin contaminant from the venipuncture site. This was a crucial step in clinical reasoning, preventing a misdiagnosis of sepsis and the administration of unnecessary antibiotics. Finally, the Radiology findings from the chest X-ray were unremarkable for any acute process. This was a vital negative finding, as it effectively ruled out a primary pulmonary cause, such as severe pneumonia or acute respiratory distress syndrome (ARDS), for the patient's respiratory collapse. This confirmed that his respiratory failure was neuromuscular in origin—a direct consequence of the paralysis of his diaphragm and intercostal muscles.



Figure 1. Patient demographics and baseline characteristics.



Figure 2. Timeline of key clinical events.



Figure 3. Neurological examination findings.



Figure 4. Key diagnostic investigation findings.

Figure 5 showed the two-pronged critical care strategy employed to manage the patient's life-threatening condition, elegantly divided into two distinct but concurrent pillars: immediate life support and targeted immunotherapy. This summary provides a clear insight into the aggressive, multi-faceted approach required in the intensive care unit (ICU). Pillar 1, Life Support, details the foundational interventions essential for managing the patient's acute organ failure. The central intervention was emergent endotracheal intubation with a 7.5 mm tube, a direct and necessary response to the neuromuscular respiratory collapse. The patient was placed on mechanical ventilation using Synchronized Intermittent-Mandatory Ventilation (SIMV), a mode that provides mandatory breaths while allowing the patient to trigger their own, which are then supported. The initial settings included a moderate level of support with a Positive End-Expiratory Pressure (PEEP) of 10 cmH_2O to prevent alveolar collapse (atelectasis) and an FiO_2 of 60% to correct hypoxemia. This pillar also highlights the importance of the comprehensive supportive care bundle—the cornerstone of modern critical care—which includes invasive monitoring for hemodynamic stability, nutritional support to prevent malnutrition, and prophylaxis against deep vein thrombosis and stress ulcers, all of which are critical to preventing complications in an immobilized patient. Pillar 2, Immunotherapy, outlines the targeted counter-offensive against the underlying autoimmune disease itself. The chosen modality was therapeutic plasma exchange (TPE), a method designed to physically remove the pathogenic autoantibodies and other inflammatory mediators from the bloodstream. The most scientifically noteworthy aspect of this pillar was the frequency: a single session. This is a significant deviation from standard multi-session protocols. The procedure was performed via a temporary hemodialysis catheter, with a substantial volume of 2500 ml of plasma exchanged for a replacement solution of albumin and saline. The report that no adverse events occurred during the procedure indicates that the intervention was well-tolerated from a hemodynamic and clinical standpoint.

Figure 5. Intensive care unit interventions.

3. Discussion

The findings of this case report present a compelling, albeit anecdotal, clinical scenario: a patient with the most severe form of AMAN-GBS, requiring mechanical ventilation, who demonstrated an unusually rapid recovery following a single session of TPE.[9] This observation stands in stark contrast to the established, evidence-based standard of care, which dictates a multi-session course of immunotherapy. While it is imperative to acknowledge that the natural history of the disease is the most likely explanation for the patient's improvement, the case provides a unique intellectual opportunity to explore the intricate dance between the host immune response and the mechanism of TPE. To understand how TPE might work, one must first appreciate the specific pathology it is intended to disrupt. Unlike the demyelinating form of GBS (AIDP), which is largely cell-mediated, AMAN is a quintessential humoral autoimmune disease.[10] The pathogenic cascade is elegant in its specificity and devastating in its effect.[11] The primary weapons of the autoimmune assault are IgG autoantibodies. Following a trigger, such as a *C. jejuni* infection, the immune system produces antibodies against bacterial surface antigens. Due to molecular mimicry, these antibodies cross-react with specific gangliosides—complex glycolipids that are densely clustered on the axolemma of human motor nerves, particularly at the nodes of Ranvier. The primary targets in AMAN are the gangliosides GM1 and GD1a.[11] The binding of these IgG antibodies to the nodal axolemma is the initiating event of nerve injury. The binding of IgG antibodies to their targets serves as a potent trigger for the classical complement pathway. The Fc portion of the bound IgG molecule recruits C1q, initiating a proteolytic cascade that rapidly amplifies. This cascade culminates in the formation of C3 convertase and subsequently C5 convertase on the surface of the axon. The key effector mechanism of this complement activation is the formation of the C5b-9 complex, also known as the membrane attack complex (MAC).[12] Molecules of C5b, C6, C7, C8, and multiple copies of C9 assemble to form a transmembrane pore directly in the axolemma. This pore disrupts the ionic gradient, leading to an influx of calcium and water, causing axonal swelling, dysfunction of voltage-gated sodium channels, and ultimately, axonal degeneration. Pathological studies of AMAN nerves show MAC deposits at the nodes of Ranvier, providing direct evidence for this mechanism of injury. This entire process—antibody binding, complement activation, and MAC-mediated damage—occurs within the intravascular and interstitial fluid compartments.[13] The key pathogenic players are all large macromolecules circulating in the plasma: IgG antibodies, complement proteins (C1q, C3, C5), and inflammatory cytokines. This makes the bloodstream a target-rich environment for an extracorporeal therapy like TPE, which is designed specifically to remove such macromolecules.

TPE physically removes the patient's plasma and replaces it with a colloid solution, thereby non-selectively clearing all large molecules. While often thought of simply as a method of "antibody washing," its therapeutic effect is likely more complex.[14] A single, large-volume plasma exchange can acutely and profoundly alter the entire humoral immune environment. This is the most direct and obvious mechanism. A 1.0 to 1.5 plasma volume exchange can remove 60-70% of the circulating intravascular IgG. TPE removes all plasma proteins, including the full array of complement factors. This can cause a temporary but deep state of "complementoplegia," halting the formation of new MAC pores. The autoimmune process is associated with the release of pro-inflammatory cytokines like TNF-α, IL-1, and IL-6, which can perpetuate the immune response and contribute to nerve damage.[14] TPE effectively removes these circulating cytokines. The concentration of pathogenic autoantibodies in GBS is not static. It follows a dynamic curve, rising after the initial immune trigger, reaching a peak concentration, and then naturally declining as the immune response wanes and clearance mechanisms take over. The clinical severity of the disease, particularly the rate of progression and the depth of the nadir, often correlates with the titer of these antibodies.[15] It is therefore entirely conceivable that this patient's clinical nadir—his point of maximum weakness requiring mechanical ventilation—coincided precisely with the absolute peak of his circulating anti-GM1/GD1a antibody titer.

If the single TPE session was performed at this exact moment of peak concentration, its therapeutic impact would be maximized. It would have removed the largest possible burden of pathogenic antibodies from the intravascular compartment in a single, decisive stroke. While antibody redistribution from the extravascular space would still occur, the total body burden of antibodies would have been significantly and abruptly blunted. The natural decline in antibody production, which may have already begun at this late stage (over three weeks into the illness), combined with this massive, acute removal, could have collectively dropped the circulating antibody concentration below a critical threshold required to sustain the autoimmune attack.[15] In this model, the timing of the intervention was everything. A TPE session performed a few days earlier might have been less effective because antibody production was still accelerating and would have rapidly replaced the removed antibodies. Conversely, a session performed a few days later might have been less impactful as the natural decline was already well underway, making the intervention somewhat redundant. The single session may have acted as a "decapitating strike" on the peak of the humoral assault, fundamentally altering the subsequent disease course in a way that a more gradual, multi-session approach might not.[16] This abrupt removal may also alter the feedback loops that regulate B-cell activity, potentially hastening the shutdown of the pathogenic antibody production line.

The ultimate executioner of axonal damage in AMAN is not the antibody itself, but the complement cascade it initiates. This cascade is a powerful biological amplification system; a single antibody molecule bound to the axolemma can lead to the deposition of hundreds of MAC pores, each capable of causing significant cellular injury.[16] This amplification dynamic suggests that the availability of complement components could be a rate-limiting step in the pathological process. If the fuel for the fire is removed, the fire goes out, even if the spark (the antibody) remains. A single, large-volume TPE session induces a profound, albeit temporary, depletion of all circulating complement proteins. This could have acted as a highly effective "complement firebreak." Even as pathogenic antibodies began to re-equilibrate back into the plasma from the tissues, there may have been insufficient levels of C1, C4, C2, C3, and especially the terminal pathway components C5 through C9, to efficiently form new MAC complexes. This would create a critical therapeutic window of several hours to a couple of days during which the axonal membrane is protected from further attack, despite the continued presence of autoantibodies. This pause in the immunological assault may have been sufficient for endogenous cellular repair mechanisms to begin their work. Cells have mechanisms to remove MAC pores from their membranes and to repair the resulting lesions.[17] By halting the continuous formation of new pores, the TPE session could have tipped the balance from a state of overwhelming, progressive injury towards one of net repair. The rapid clinical improvement seen in this patient—particularly the restoration of respiratory muscle function sufficient for extubation—is more consistent with the reversal of a physiological blockade (such as that caused by MAC-induced ion channel dysfunction and membrane depolarization) than with the much slower process of axonal regeneration. A sudden halt in MAC formation could plausibly allow for the rapid restoration of nerve conduction in axons that were dysfunctional but not yet irreversibly damaged, leading to a swift functional recovery.[17]

The standard multi-session TPE protocol is based on the average pharmacokinetics of IgG redistribution in a general patient population. Following a TPE session, IgG levels in the plasma typically rebound to about 60-80% of their pre-treatment levels within 48 hours as extravascular IgG moves into the circulation.[17] The rate of this re-equilibration, however, is not a biological constant and may not be uniform across all individuals. It can be influenced by a host of factors, including endothelial vascular permeability, lymphatic flow, overall metabolic state, and the presence of critical illness. This patient was a 68-year-old man in a state of septic shock-like systemic inflammation, a condition known to profoundly alter physiology. Critical illness is often associated with increased capillary leak and "third-spacing" of fluid and proteins, including immunoglobulins, into the interstitial space.[18] It is plausible that this patient's critical state created a

unique pharmacokinetic environment. The systemic inflammation could have led to a larger-than-usual extravascular sequestration of pathogenic antibodies. Furthermore, critical illness can impair lymphatic drainage, the primary route for returning interstitial proteins to the circulation. If this patient's lymphatic drainage was impaired, the rate of antibody re-equilibration from the extravascular to the intravascular space might have been significantly slower than average. If the rebound of pathogenic antibodies was delayed from the typical 48 hours to, perhaps, 72 or 96 hours, the therapeutic window created by the single TPE session would have been substantially extended. This prolonged period of low circulating antibody levels might have been sufficient to definitively break the cycle of inflammation and allow recovery to begin, rendering subsequent TPE sessions unnecessary.[18] This hypothesis suggests that the efficacy of TPE might be highly patient-dependent, and that our "one-size-fits-all" protocol may not account for the profound pharmacokinetic variability introduced by the patient's underlying physiological state, especially in the context of critical illness.

It is unlikely that any single one of these hypotheses alone explains the remarkable observation in this case. It is far more probable that the patient's rapid recovery resulted from a fortuitous and powerful convergence of multiple factors. The single TPE session may have been perfectly timed to coincide with the absolute peak of the patient's pathogenic antibody titer, delivering the most impactful blow to the humoral assault.[19] This "peak titer interruption" was likely potentiated by the simultaneous creation of a profound "complement firebreak," which immediately halted the effector mechanism of axonal damage. Finally, the patient's specific state of critical illness may have created an anomalous pharmacokinetic environment that slowed the re-equilibration of the remaining antibodies, prolonging the therapeutic window created by the intervention. This "perfect storm" of favorable events—perfect timing, dual-mechanism disruption, and favorable pharmacokinetics—could have synergistically produced a therapeutic effect far greater than what would be expected from a single intervention under average circumstances. This discussion is, by its nature, speculative. It is a scientific thought experiment prompted by an anomalous clinical result. It does not prove that single-session TPE is an effective therapy. However, it highlights the dynamic nature of the GBS disease process and underscores that our understanding of the intricate interplay between the immune system and our therapies is still incomplete.[19] The case serves as a powerful reminder that behind our population-based treatment protocols lie individual patients with unique physiological responses, and that studying these outliers can provide invaluable insights into the fundamental mechanisms of disease and treatment.

Figure 6 showed a detailed three-stage visual model that lucidly illustrates the pathophysiological cascade of acute motor axonal neuropathy (AMAN) and the theoretical mechanisms by which a single session of therapeutic plasma exchange (TPE) may have led to the patient's rapid recovery. The figure provides a comprehensive narrative, from the initial autoimmune trigger to the ultimate clinical resolution. Stage 1: Immune Trigger & Autoantibody Production. The model begins by outlining the initiation of the autoimmune response. This stage is predicated on an antecedent event, most commonly an infection such as with *Campylobacter jejuni*. The central pathogenic theory of molecular mimicry is introduced, explaining how bacterial antigens bear a strong resemblance to the body's own nerve gangliosides. This unfortunate similarity leads the immune system to make a critical error. In the process of mounting an attack against the foreign pathogen, the body’s B-cells are triggered to produce pathogenic IgG autoantibodies, specifically targeting gangliosides like GM1 and GD1a, which are crucial components of nerve cell membranes. This first stage effectively sets the scene for a case of mistaken identity, where the body's own defense system is primed to attack itself.

Figure 6. Pathophysiology of AMAN and hypothesized therapeutic mechanism.

Stage 2: Axonal Damage & Clinical Manifestation. The second stage provides a clear depiction of the autoimmune attack on the motor nerve, detailing the precise mechanism of injury. The pathogenic IgG autoantibodies, produced in Stage 1, now circulate and find their targets on the motor axolemma, binding specifically to the GM1/GD1a gangliosides, which are highly concentrated at the nodes of Ranvier. This

binding event is the catalyst for the subsequent destructive cascade. Figure 6 illustrates that this antibody binding immediately activates the classical complement cascade, a powerful amplification system of the innate immune response. The bound IgG acts as a flag, summoning complement proteins to the site of the attack. This cascade culminates in the formation of the membrane attack complex (MAC), a formidable molecular structure that inserts destructive pores directly into the axon's cell membrane. The clinical result of this molecular damage is profound and devastating. The pores disrupt the axon's integrity, leading to severe axonal damage and a blockage of nerve conduction. This translates directly into the clinical signs of flaccid paralysis and, in severe cases like the one presented, life-threatening respiratory failure as the muscles of breathing become paralyzed.

Stage 3: Therapeutic Intervention & Hypothesized Effect. The final stage of the model shifts focus from pathology to therapy, illustrating how a single, large-volume session of TPE can disrupt the pathogenic cascade. The intervention involves the bulk removal of plasma, which contains the key agents of the autoimmune attack. By performing the TPE at a critical moment, the procedure achieves an acute removal of the highest concentration of the pathogenic IgG autoantibodies circulating in the blood.[20] This single, decisive action could significantly reduce the overall burden of the primary antagonist. TPE non-selectively removes all large plasma molecules, including essential complement proteins. This abrupt depletion is hypothesized to create a "complement firebreak," halting the formation of new, destructive MAC pores even if some autoantibodies remain, effectively uncoupling the presence of the antibody from the execution of damage. The procedure also removes circulating inflammatory mediators, or cytokines, that are known to perpetuate and amplify the immune response.[20] Figure 6 concludes by linking these disruptive mechanisms to the observed clinical outcome. By simultaneously removing antibodies, halting the complement effector pathway, and washing out inflammatory mediators, the single TPE session is theorized to cause a complete cessation of the axonal attack. This halt in the ongoing damage allows for the patient's endogenous repair mechanisms to function, leading to a rapid functional recovery and clinical improvement.

4. Conclusion

This case report has meticulously documented the clinical course of a critically ill patient with the severe AMAN variant of Guillain-Barré Syndrome who exhibited an unusually rapid recovery following a single session of TPE. While we must strongly emphasize that this observation is most likely attributable to the natural history of the disease, it provides a valuable opportunity for deep pathophysiological exploration. The theoretical possibility that a single, well-timed intervention could profoundly disrupt the humoral autoimmune cascade by simultaneously depleting peak antibody titers and essential complement factors is a compelling concept that warrants consideration. This case does not provide evidence to alter the established, evidence-based, multi-session standard of care for TPE in GBS. Rather, it serves as a unique, hypothesis-generating report that underscores the complex and dynamic nature of this devastating disease and highlights avenues for future investigation into optimizing immunomodulatory therapies.

5. References

1. Maqbool M, Deekshitha K, Chandana DD, Abbas Z, Talukdar A, Mehdi A. Postpartum Guillain-Barré syndrome presenting as acute motor axonal neuropathy in a young female: a report of a rare case. Cureus. 2024; 16(10): e70787.
2. Iizuka N, Nomoto S, Kurokawa S, Kasai H, Itaya K, Ichikawa H. Ultrasonographic appearance of nerve roots in patients with guillain-barre syndrome (GBS): Comparison between acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). J Neurol Sci. 2017; 381: 491.
3. Incecik F, Herguner OM, Besen S. Finger drop sign in a child with acute motor and sensory axonal neuropathy form of Guillain-Barré syndrome. Acta Neurol Belg. 2017; 117(1): 393–4.

4. Kalita J, Kumar M, Misra UK. Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barré syndrome in India. Muscle Nerve. 2018; 57(5): 761–5.
5. Patel D, Arjun S, Sanivarapu R, Akella J, Iqbal J, Alaverdian A. Severe respiratory compromise in acute motor axonal neuropathy, a rare variant of guillain-Barré syndrome. Chest. 2019; 156(4): A1226–7.
6. de Castillo LLC, Diestro JDB, Ignacio KHD, Pasco PMD. A rare mimic of acute stroke: rapidly progressing Miller-Fisher syndrome to acute motor and sensory axonal neuropathy variant of Guillain-Barre Syndrome. BMJ Case Rep. 2019; 12(3): e228220.
7. Samadi A, Mansour-Ghanaei F, Joukar F, Mavaddati S, Sufi Afshar I. A 30-year-old man with acute motor axonal neuropathy subtype of guillain-Barré syndrome having hepatitis A virus infection. Middle East J Dig Dis. 2019; 11(2): 110–5.
8. Leon M. About a case of acute motor axonal neuropathy (AMAN), seen in our hospital, a pure motor axonal form of Guillain-Barré syndrome. J Neurol Res Rev Rep. 2020; 1–3.
9. Liu DY, Hollenbach JR, Gregorin JA, Wynbrandt JH. A case of acute motor sensory axonal neuropathy: a variant of Guillain-Barré syndrome, with possible syndrome of irreversible lithium-effectuated neurotoxicity. Case Rep Med. 2020; 2020: 4683507.
10. Huberman M, Akgun Y, Langlie J, Wu Y. Therapeutic plasma exchange in a patient with acute motor axonal neuropathy subtype of Guillain-Barre syndrome and systemic lupus erythematosus. Neurology. 2022; 99(23): S27–S27.
11. Qureshi Z, Kandhi S, Prasai N, Altaf F, Dhallu M. COVID-19-associated autoimmune disease: A rare first case report of acute motor axonal neuropathy variant of Guillain-Barre syndrome in a woman patient in New York City. Cureus. 2022; 14(2): e22290.
12. Alzuhaily H, Khashaneh E, Albkhetan S, Abbas F. An unusual occurrence of opsoclonus and liver enzymes elevation in a patient with acute motor and sensory axonal neuropathy subtype of Guillain-Barré syndrome. BMC Neurol. 2022; 22(1): 102.
13. Erdurmus OY, Erhan A, Genc S, Oguz AB, Koca A, Günalp M, et al. The acute motor axonal neuropathy variant of Guillain–Barré Syndrome diagnosed after ankle trauma. Turk J Emerg Med. 2022; 22(3): 166–8.
14. Akgun Y, Langlie J, Huberman MA, Wu Y. Therapeutic plasma exchange in a patient with acute motor axonal neuropathy subtype of Guillain-Barre syndrome and systemic lupus erythematosus. J Clin Apher. 2022; 37(4): 405–10.
15. Braun S, Bastian L, Hayes C, Owen SC, Craig C, Nelson A. Systemic lupus erythematosus initially presenting as acute motor and sensory axonal neuropathy variant of Guillain-Barre syndrome in a healthy active duty female. Mil Med. 2024; 189(3–4): e915–8.
16. Wanninayake L, Rajapaksha D, Nair N, Gunarathne K, Ranawaka U. Guillain-Barre syndrome of acute motor axonal neuropathy (AMAN) type associated with herpes zoster: a case report. BMC Neurol. 2024; 24(1): 109.
17. Hernandez E, Dominguez D, Medina-Rioja R, Martínez-Angeles V, López-Hernández JC. Treatment-related fluctuation in Guillain-barre syndrome with the acute motor-sensory axonal neuropathy (AMSAN) variant: a case report. Cureus. 2024; 16(7): e65201.
18. Imajoh M, Mori M, Shimizu T, Koizumi Y, Kobayashi Y, Kawahara M, et al. Complete genome sequence of Edwardsiella tarda strain GBS0709 isolated from a Japanese patient with the acute motor axonal neuropathy subtype of Guillain-Barré syndrome. Microbiol Resour Announc. 2024; 13(9): e0045624.
19. Poulose PV, Tham S-L. Acute motor and sensory axonal neuropathy variant Guillain-Barre syndrome related to coronavirus disease

2019: Rehabilitation challenges and pitfalls. J Int Soc Phys Rehabil Med. 2025.
20. Sharom MAI, Md Noor J, Mokhtar MF. Rare abdominal pain onset in Guillain-Barré syndrome: a case report of acute motor sensory axonal neuropathy. Am J Case Rep. 2025; 26: e946737.